Chennai Company Announces U.S. Food and Drug Administration Clearance for Wearable Medical Device to Treat Drug Addiction

Tuesday, June 12, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

CHENNAI, India, June 12, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration has cleared an auricular neurostimulation

device manufactured by a Chennai company to treat the symptoms of opioid withdrawal without narcotics. The device, Drug Relief®, is made by DyAnsys India for its U.S. affiliate, DyAnsys Inc.

Drug Relief®, is available

by prescription for use during opioid detoxification. This wearable device sends electrical pulses through tiny needles inserted in the ear to alleviate symptoms such as anxiety, agitation, depression, nausea, opiate cravings and more.

"This device offers hope to those who are suffering from opioid addiction," said DyAnsys Chief Executive Officer Srini Nageshwar, a graduate of the Institute of Technology Madras. "We are in a full-blown crisis and we need non-narcotic options and alternatives like this that can make a significant difference for individual patients and their families."

Nearly 30 million people, or 0.6 percent of the adult population worldwide, were engaged in problematic drug use and suffered from disorders in 2015, according to the United Nations Office on Drugs and Crime. Opioids accounted for 70 percent of the negative health impact associated with drug use disorders UNDOC reported in last year's World Drug Report.

Drug Relief® is a percutaneous electrical nerve field stimulator designed to administer auricular neurostimulation treatment over 120 hours. The non-addictive treatment allows for continuous nerve stimulation for five days while offering the patient a high degree of comfort and mobility. According to providers, patients may see a reduction in symptoms within 30 to 60 minutes of beginning treatment.

The device eases detoxification, the first step in a comprehensive rehabilitation program. The objective is to relieve symptoms while opioids are cleared from a patient's system. It can be used to stabilize a patient during the early stages of withdrawal without side effects. Stabilization necessary before treating the patient with medication-assisted therapies.

Information is available at mydrugrelief.com.

DyAnsys provides innovative medical solutions that combine exclusive research on the autonomic nervous system (ANS) and insights regarding its involvement in chronic pain treatment. The company develops, manufactures and distributes the ANSiscope®, which provide the highest fidelity representations of the ANS available, and Primary Relief™, a percutaneous nerve stimulator, to treat chronic pain without narcotics.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store